Seattle Genetics shares are trading higher after Piper Jaffray maintained an Overweight rating on the stock and raised the price target from $75 to $95. Seattle Genetics presented compelling initial data from the EV-103 study, which compared favorably to the current standard of care. Piper Jaffray also sees the potential for further upside from additional UBS opportunities.